Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01595724
Other study ID # 16108
Secondary ID VS1101
Status Completed
Phase N/A
First received May 9, 2012
Last updated July 9, 2015
Start date May 2012
Est. completion date May 2015

Study information

Verified date July 2015
Source Bayer
Contact n/a
Is FDA regulated No
Health authority Belarus: Ministry of HealthKazakhstan: Ethical Commission, Ministry of Public Health, National Center for Expertise of Drugs, Medical Products and EquipmentUkraine: Ethics Committee, Ministry of Health, State Pharmacological CenterRussia: Ethics Committee, FSI Scientific Center of Expertise of Medical Application, Ministry of Health and Social Development of the Russian Federation
Study type Observational

Clinical Trial Summary

The study aims to collect data on the influence of a treatment with Visanne (Dienogest 2mg/d) on the Endometriosis related quality of life. These data will be collected using a special patient questionnaire (Endometriosis Health Profile 5, EHP-5). The study will also be used to describe the basic disease status and demographic characteristics of patients searching treatment by a gynecologist because of their endometriosis. In addition, the study will give insight into the typical diagnostic measures the physicians in different countries are using in the field of endometriosis.


Recruitment information / eligibility

Status Completed
Enrollment 3006
Est. completion date May 2015
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Female patients older than 18 years of age

- Clinical or laparoscopic diagnosis of endometriosis

- Having endometriosis related pain as leading symptom

- Decision taken by physician to prescribe Visanne

- Signed Informed Consent Form

Exclusion Criteria:

- Contraindications listed in the local summary of product characteristics (SPC) have to be considered.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
Visanne (Dienogest, BAY86-5258)
Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Countries where clinical trial is conducted

Belarus,  Egypt,  Jordan,  Kazakhstan,  Kuwait,  Lebanon,  Qatar,  Russian Federation,  Saudi Arabia,  Ukraine,  United Arab Emirates, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients, who show an improvement of the EHP-5 items after 6 months of treatment No
Primary Mean changes of EHP-5 items by using scores for pre-defined categories after 6 months of treatment No
Secondary Baseline demographic characteristics and disease status of patients with endometriosis treated with Visanne Baseline No
Secondary Patient reported severity of endometriosis related pain Baseline and after 6 months of treatment No
Secondary Reasons for treatment discontinuation after 6 months of treatment No
Secondary Safety variables will be summarized using descriptive statistics based on adverse events collection after 6 months of treatment Yes
See also
  Status Clinical Trial Phase
Completed NCT01931670 - A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain Phase 3
Recruiting NCT05648669 - A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain Phase 3
Completed NCT04081532 - The Effectiveness of Laparoscopic Treatment of Superficial Endometriosis for Managing Chronic Pelvic Pain N/A
Recruiting NCT06101303 - Endometriosis Pain
Completed NCT04665414 - Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
Completed NCT03690765 - Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis
Recruiting NCT05153512 - ADOlescent DysmenoRrhea Endometriosis Assessment Magnetic Resonance Imaging (Adodream)
Active, not recruiting NCT04171297 - Ultrasound Evaluation of the Pelvis in Women With Suspected Endometriosis Scheduled for Laparoscopic Surgery
Recruiting NCT04172272 - The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures N/A
Completed NCT04565470 - Strategies of Self-management of Endometriosis Symptoms
Completed NCT03613298 - Treatment by HIFU With Focal One® of Posterior Deep Infiltrating Endometriosis Lesions With Intestinal Involvement. N/A
Withdrawn NCT05568940 - Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
Not yet recruiting NCT03464799 - Does Immunotherapy Have a Role in the Management of Endometriosis?
Active, not recruiting NCT03002870 - Characteristics of Patient Population With Endometriosis N/A
Completed NCT02973854 - Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Endometriosis: Identification of Potential Relevant Biomarkers to Diagnose and Treat
Withdrawn NCT03272360 - Endometriosis Biomarker Discovery Study N/A
Recruiting NCT02481739 - Laparoscopic Surgical Management of Endometriosis on Fertility N/A
Active, not recruiting NCT02754648 - Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve N/A
Completed NCT06106932 - GnRH-a on Angiogenesis of Endometriosis N/A
Completed NCT02387931 - Supplementation in Adolescent Girls With Endometriosis Phase 4